A new theranostic target in prostate cancer: First results from prostatic acid phosphatase (ACP3) imaging with [68Ga] Ga-OncoACP3-DOTA PET in prostate cancer …
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://jnm.snmjournals.org/content/66/supplement_1/251856.abstract
其他信息:
P Backhaus, K Seitzer, S Cazzamalli, S Oehler…
2025
jnm.snmjournals.org
251856 Introduction: Prostate-specific membrane antigen (PSMA) theranostics play an extraordinary role in prostate cancer (PC) management. However, not all PC lesions show sufficient PSMA expression to facilitate diagnostic PET and radioligand treatment. Prostatic acid phosphatase (ACP3) shows high expression in most PC lesions and barely any expression in healthy organs (except for the healthy prostate). Recently, a first-in-class high-affinity ACP3 ligand was isolated from a DNA-encoded chemical library (Cazzamalli et al. J …
